Our proprietary technologies, EpitoPredikt^TM and EpitoGen®, are key to providing high-quality antibodies. The EpitoPredikt^TM software screens targets to identify antigenic regions, which are then synthesized and displayed on our EpitoGen® scaffold to be used for generating antibodies. EpitoGen® also provides a unique method for fast-tracking the screening process to ensure an efficient identification of desired clones.

Our platform’s key advantages include:

• Flexibility – multiple epitopes with a wide range of lengths (5 to 600 amino acids) can be expressed and used for immunisation.
• High success rates and specific antibodies – epitopes displayed on our EpitoGen® scaffold are presented in the correct conformation.
• High throughput and cost-effective screening process for the desired clones.
• Suitable to develop antibodies against multiple candidates simultaneously.

Check out our product catalogue at Vertebrate Antibodies LTD and Ximbio.